A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee

Trial Profile

A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Taiwan Liposome Company
  • Most Recent Events

    • 25 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 03 Jan 2017 According to a Taiwan Liposome Company media release, data will be un-blinded once the 24 week follow-up period is up for all 72 patients.
    • 03 Jan 2017 According to a Taiwan Liposome Company media release, company announced the approval of an investigational new drug (IND) application for this study of TLC599.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top